• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
  • Podcasts
  • Resources
    • Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

HDAC

Research

Could inhibiting both HDAC and PD-1 improve I-O treatments?

OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.
Arlene Weintraub Jun 24, 2019 10:30am

Viracta's combo garners high response in EBV-linked lymphoma

Jun 3, 2019 11:39am

Xynomic preps broad push for HDAC cancer drug

Jun 1, 2018 10:26am

Syndax pals up with Nektar on entinostat combo trial

May 31, 2018 10:10am

Syndax touts possible biomarker data in HDAC/PD-1 combo in NSCLC

May 17, 2018 10:29am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
  • ©2022 Questex LLC All rights reserved.
  • Terms of use
  • Privacy Policy